Progress in clinical neurosciences: A systematic review of the use of triptans in acute migraine

Canadian Journal of Neurological Sciences

Volumn 28, Issue 1, 2001, Pages 30-41

  Gawel, M J ^a   Worthington, I ^a   Maggisano, A ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CIPROFLOXACIN; ERGOT DERIVATIVE; FLUVOXAMINE; MAXALT RPD; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; PROPRANOLOL; RIZATRIPTAN; SEROTONIN 1 AGONIST; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN SUCCINATE; ZOLMITRIPTAN; DRUG DERIVATIVE; SEROTONIN AGONIST; SUMATRIPTAN;

CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; HUMAN; MIGRAINE; NEUROSCIENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; ACUTE DISEASE; DRUG INTERACTION;

ACUTE DISEASE; DRUG INTERACTIONS; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0035259823     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100052525     Document Type: Review

References (74)

1. Treatment of acute migraine with subcutaneous sumatriptan
2. Treatment of migraine attacks with sumatriptan
3. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat
4. Guidelines for the diagnosis and management of migraine in clinical practice
5. Guidelines for the nonpharmacological management of migraine in clinical practice
6. Pathophysiology of migraine - New insights
7. Triptans and migraine: Which drug for which patient?
8. The clinical pharmacokinetics of zolmitriptan
9. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine
10. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90)
11. Serotonin syndrome complicating migraine pharmacotherapy
12. Sumatriptan contraindications and the serotonin syndrome
13. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers
14. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)
15. Lack of an interaction between propranolol and sumatriptan
16. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine
17. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine
18. Rizatriptan vs. sumatriptan in the acute treatment of migraine
19. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine
20. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
21. Migraine symptoms: Results of a survey of self-reported migraineurs
22. Oral sumatriptan: Effect of a second dose, and incidence and treatment of headache recurrences
23. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine
24. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine
25. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan long-term study group
26. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study
27. 311C90: Long-term efficacy and tolerability profile for the acute treatment of migraine
28. A long-term study to maximize migraine relief with zolmitriptan
29. Zolmitriptan provides consistent migraine relief when used in the long term
30. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan
31. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks
32. Naratriptan is effective and well-tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study
33. Naratriptan is effective and well-tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study
34. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine
35. Coronary side-effect potential of current and prospective antimigraine drugs
36. Interim results from the sumatriptan pregnancy registry
37. Pregnancy outcome following prescription for sumatriptan
38. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study
39. Clinical applications of zolmitriptan (Zomig, 311C90)
40. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
41. Low migraine headache recurrence with naratriptan: Clinical parameters related to recurrence
42. Treatment of oral sumatriptan nonresponders with 5 mg zolmitriptan and 10 mg rizatriptan: A comparative open trial
43. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan
44. Sumatriptan and ergotamine overuse and drug-induced headache: A clinicoepidemiologic study
45. Inappropriate use of sumatriptan: Population based register and interview study
46. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device
47. Sumatriptan in acute migraine using a novel cartridge system self-injector
48. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine
49. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice
50. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose system
51. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice
52. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine
53. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine
54. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine
55. Optimizing the dose of zolmitriptan (Zomig,* 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study
56. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
57. Sumatriptan - An oral dose-defining study
58. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine
59. Oral sumatriptan in acute migraine
60. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths
61. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: Results of a multicenter study
62. Oral sumatriptan compared with placebo in the acute treatment of migraine
63. Valutazione dell'efficacia di sumatriptan nella terapia orale dell'attacco di emicrania. Resultati clinici
64. Clinical experience with oral sumatriptan: A placebo-controlled, dose-ranging study
65. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine
66. Oral sumatriptan for the long-term treatment of migraine: Clinical findings
67. Early experience with subcutaneous naratriptan in the acute treatment of migraine: A dose-ranging study
68. Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group
69. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies